Who owns BRIDGEBIO ONCOLOGY THERAPEUT?
- Ticker: BBOT
- CUSIP Number: 107924102
Tip: Access positions for across all investors
Analyze quarterly positions in Bridgebio Oncology Therapeut with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Bridgebio Oncology Therapeut stock
Who bought or sold BRIDGEBIO ONCOLOGY THERAPEUT this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Cormorant Asset Management | 18M | $136M | 0% | Jun 2026 |
|
| Deerfield Management Company | 4.9M | $37M | 0% | Jun 2026 |
|
| Omega Fund Management | 3.3M | $25M | 0% | Jun 2026 |
|
| EcoR1 Capital | 2.8M | $22M | 0% | Jun 2026 |
|
| Alphabet | 2.8M | $22M | 0% | Jun 2026 |
|
| Wellington Management Company | 2.8M | $21M | -1% | Jun 2026 |
|
| Enavate Sciences GP | 2.6M | $20M | 0% | Jun 2026 |
|
| Citadel Advisors | 2.6M | $20M | 4% | Jun 2026 |
|
| Novo A/S | 2.3M | $17M | 3% | Jun 2026 |
|
| BlackRock | 2.2M | $16M | 3% | Jun 2026 |
|
| Vanguard Capital Management | 2.0M | $15M | 272% | Jun 2026 |
|
| Laurion Capital Management | 2.0M | $15M | 4% | Jun 2026 |
|
| Armistice Capital | 1.8M | $13M | 33% | Jun 2026 |
|
| Aisling Capital Management | 1.0M | $7.8M | 0% | Jun 2026 |
|
| Opaleye Management | 700k | $5.3M | 1214% | Jun 2026 |
|
| Geode Capital Management | 622k | $4.7M | 7% | Jun 2026 |
|
| Granahan Investment Management | 559k | $4.3M | 142% | Jun 2026 |
|
| Sphera Funds Management | 461k | $3.5M | 100% | Jun 2026 |
|
| T. Rowe Price Associates | 438k | $3.9M | -45% | Mar 2026 |
|
| Adage Capital Partners GP | 400k | $3.0M | 0% | Jun 2026 |
|
| Royce & Associates | 385k | $2.9M | -40% | Jun 2026 |
|
| Catalio Capital Management | 318k | $2.4M | 100% | Jun 2026 |
|
| Vanguard Fiduciary Trust | 292k | $2.2M | 15% | Jun 2026 |
|
| Charles Schwab Investment Management | 287k | $2.2M | -1% | Jun 2026 |
|
| Sixth Street Partners Management Company | 287k | $2.2M | 100% | Jun 2026 |
|
| Casdin Capital | 282k | $2.2M | 0% | Jun 2026 |
|
| Ensign Peak Advisors | 274k | $2.1M | -15% | Jun 2026 |
|
| Schroder Investment Management Group | 244k | $1.9M | -2% | Jun 2026 |
|
| FMR | 241k | $1.8M | 0% | Jun 2026 |
|
| State Street Corporation | 226k | $2.0M | 4% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 191k | $1.5M | 110% | Jun 2026 |
|
| Northern Trust | 187k | $1.4M | 82% | Jun 2026 |
|
| Sio Capital Management | 131k | $995k | 0% | Jun 2026 |
|
| UBS Group | 115k | $874k | 127% | Jun 2026 |
|
| Millennium Management | 106k | $804k | -60% | Jun 2026 |
|
| Goldman Sachs Group | 102k | $778k | -39% | Jun 2026 |
|
| Moore Capital Management | 100k | $762k | 0% | Jun 2026 |
|
| Tema Etfs | 93k | $711k | 14% | Jun 2026 |
|
| Toroso Investments | 93k | $711k | 14% | Jun 2026 |
|
| Brevan Howard Capital Management | 89k | $691k | 524% | Jun 2026 |
|
| Palumbo Wealth Management | 86k | $653k | 100% | Jun 2026 |
|
| Bank of America Corporation | 77k | $588k | 100% | Jun 2026 |
|
| Jump Financial | 62k | $472k | 100% | Jun 2026 |
|
| Renaissance Technologies | 59k | $447k | -42% | Jun 2026 |
|
| Avidity Partners Management | 44k | $334k | 0% | Jun 2026 |
|
| Morgan Stanley | 43k | $388k | 202% | Mar 2026 |
|
| TD Asset Management | 43k | $326k | -26% | Jun 2026 |
|
| Virtus Investment Advisers | 42k | $322k | 100% | Jun 2026 |
|
| Manufacturers Life Insurance Company | 28k | $213k | -22% | Jun 2026 |
|
| Two Sigma Investments | 27k | $202k | 100% | Jun 2026 |
|
| Rafferty Asset Management | 23k | $172k | 100% | Jun 2026 |
|
| Squarepoint Ops | 20k | $150k | -54% | Jun 2026 |
|
| Vanguard Global Advisers | 18k | $138k | 0% | Jun 2026 |
|
| Schonfeld Strategic Advisors | 12k | $88k | 100% | Jun 2026 |
|
| ProFund Advisors | 11k | $84k | 100% | Jun 2026 |
|
| Axq Capital | 11k | $82k | -38% | Jun 2026 |
|
| Mirae Asset Global Etfs Holdings | 2.6k | $20k | 100% | Jun 2026 |
|
| Barclays | 2.1k | $16k | 890% | Jun 2026 |
|
| Tower Research Capital | 1.7k | $13k | 100% | Jun 2026 |
|
| Northwestern Mutual Wealth Management Company | 1.4k | $10k | 100% | Jun 2026 |
|
| Rockefeller Capital Management | 1.0k | $7.6k | 43% | Jun 2026 |
|
| Pacer Advisors | 378.00 | $3.0k | 100% | Jun 2026 |
|
| Wells Fargo & Company | 300.00 | $2.3k | 0% | Jun 2026 |
|
| Quarry | 197.00 | $1.5k | 100% | Jun 2026 |
|
| Caitong International Asset Management | 37.00 | $281.999200 | 825% | Jun 2026 |
|
Who sold out of Bridgebio Oncology Therapeut?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Paradigm Biocapital Advisors | Mar 2026 | 868k | $7.8M |
| Octagon Capital Advisors | Mar 2026 | 719k | $6.4M |
| Eventide Asset Management | Mar 2026 | 541k | $4.7M |
| Ikarian Capital | Mar 2026 | 270k | $2.4M |
| Hudson Bay Capital Management | Mar 2026 | 110k | $985k |
| Woodline Partners | Mar 2026 | 104k | $928k |
| Boothbay Fund Management | Mar 2026 | 81k | $724k |
| HighVista Strategies | Mar 2026 | 78k | $700k |
| Qube Research & Technologies | Mar 2026 | 72k | $644k |
| XTX Topco | Mar 2026 | 60k | $535k |
| Acadian Asset Management | Mar 2026 | 29k | $260k |
| Diametric Capital | Mar 2026 | 16k | $146k |
| Quadrature Capital | Mar 2026 | 13k | $120k |
| Aquatic Capital Management | Mar 2026 | 12k | $106k |
| Bellevue Group | Mar 2026 | 7.0k | $63k |
| Royal Bank of Canada | Mar 2026 | 154.00 | $999.999000 |